WallStSmart

Astrana Health Inc (ASTH)vsThe Ensign Group Inc (ENSG)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

The Ensign Group Inc generates 59% more annual revenue ($5.06B vs $3.18B). ENSG leads profitability with a 6.8% profit margin vs 0.7%. ENSG trades at a lower P/E of 35.0x. ENSG earns a higher WallStSmart Score of 57/100 (C).

ASTH

Hold

46

out of 100

Grade: D+

Growth: 7.3Profit: 4.5Value: 3.0Quality: 5.0

ENSG

Buy

57

out of 100

Grade: C

Growth: 8.0Profit: 6.0Value: 8.0Quality: 5.8
Piotroski: 5/9Altman Z: 2.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ASTHSignificantly Overvalued (-508.0%)

Margin of Safety

-508.0%

Fair Value

$3.13

Current Price

$24.48

$21.35 premium

UndervaluedFair: $3.13Overvalued
ENSGFair Value (-0.3%)

Margin of Safety

-0.3%

Fair Value

$211.28

Current Price

$203.89

$7.39 premium

UndervaluedFair: $211.28Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ASTH2 strengths · Avg: 9.0/10
Revenue GrowthGrowth
42.9%10/10

Revenue surging 42.9% year-over-year

Price/BookValuation
1.5x8/10

Reasonable price relative to book value

ENSG1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
20.2%8/10

Revenue surging 20.2% year-over-year

Areas to Watch

ASTH4 concerns · Avg: 3.0/10
Market CapQuality
$1.35B3/10

Smaller company, higher risk/reward

Return on EquityProfitability
4.5%3/10

ROE of 4.5% — below average capital efficiency

Profit MarginProfitability
0.7%3/10

0.7% margin — thin

Operating MarginProfitability
1.8%3/10

Operating margin of 1.8%

ENSG3 concerns · Avg: 3.7/10
PEG RatioValuation
1.784/10

Expensive relative to growth rate

P/E RatioValuation
35.0x4/10

Premium valuation, high expectations priced in

Profit MarginProfitability
6.8%3/10

6.8% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : ASTH

The strongest argument for ASTH centers on Revenue Growth, Price/Book. Revenue growth of 42.9% demonstrates continued momentum.

Bull Case : ENSG

The strongest argument for ENSG centers on Revenue Growth. Revenue growth of 20.2% demonstrates continued momentum.

Bear Case : ASTH

The primary concerns for ASTH are Market Cap, Return on Equity, Profit Margin. A P/E of 52.7x leaves little room for execution misses. Thin 0.7% margins leave little buffer for downturns.

Bear Case : ENSG

The primary concerns for ENSG are PEG Ratio, P/E Ratio, Profit Margin.

Key Dynamics to Monitor

ASTH profiles as a hypergrowth stock while ENSG is a growth play — different risk/reward profiles.

ASTH carries more volatility with a beta of 0.90 — expect wider price swings.

ASTH is growing revenue faster at 42.9% — sustainability is the question.

ENSG generates stronger free cash flow (133M), providing more financial flexibility.

Bottom Line

ENSG scores higher overall (57/100 vs 46/100) and 20.2% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Astrana Health Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Astrana Health, Inc., Inc., a physician-centric technology-powered healthcare management company, provides medical care services in the United States. The company is headquartered in Alhambra, California.

The Ensign Group Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

The Ensign Group, Inc. provides health care services in the post-acute care continuum and other ancillary businesses. The company is headquartered in San Juan Capistrano, California.

Want to dig deeper into these stocks?